Evidence map›Paper›PMID 40884186›Full record

ReviewEndocrinology2025

The Hypothalamic-Pituitary-Ovarian Axis, Ovarian Disorders, and Brain Aging.

Heather Valera, Angela Chen, Kathryn J Grive

Abstract readReview
In one paragraph

Review in Endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Effects of Total Flavonoids FromFood science & nutrition · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. SheVari4Food & nutrition research · 2026
    Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Heather ValeraMolecular Biology, Cell Biology, and Biochemistry Graduate Program, Brown University, Providence, RI 02906, USA.ORCID 0009-0002-0774-2173
Angela ChenDepartment of Obstetrics and Gynecology, Program in Women's Oncology, Women and Infants Hospital of Rhode Island, Providence, RI 02905, USA.ORCID 0009-0009-3025-0864
Kathryn J GriveDepartment of Obstetrics and Gynecology, Program in Women's Oncology, Women and Infants Hospital of Rhode Island, Providence, RI 02905, USA.ORCID 0000-0002-7102-817X

Funding

Requirement for Ubiquitin C-Terminal Hydrolase function in mammalian ovarian health and fertilityR01HD111322 · NICHD · WOMEN AND INFANTS HOSPITAL-RHODE ISLAND · PI Kathryn J Grive · 2024 to 2026
$1.2M
National Institute for Child Health and Development R01-HD111322NICHD NIH HHS R01 HD111322NIH HHS
6 · The paper itself

Abstract

The hypothalamic-pituitary-ovarian (HPO) axis is a complex endocrine feedback mechanism controlling ovulation in female vertebrates. Balance of the HPO axis requires correct secretion of sex steroids from the ovarian follicle to inhibit release of gonadotropins from the pituitary. Several conditions of ovarian dysfunction such as menopause, primary ovarian insufficiency, and polycystic ovary syndrome involve imbalances in the HPO axis, contributing to infertility. Intriguingly, these disorders also share a higher incidence of cognitive and emotional dysregulations, as well as a heightened risk of certain neurodegenerative conditions with age. It is understood that estradiol exerts neuroprotective functions, but gonadotropin signaling is less understood. High concentrations of circulating follicle-stimulating hormone (FSH) and luteinizing hormone (LH) have shown to contribute to neurodegenerative disease states, but are not addressed as part of traditional hormone replacement therapy. To identify the mechanistic connections between ovarian disorders and heightened susceptibility of the brain to pathological aging, a multisystem experimental approach is required, considering each HPO axis player as an individual effector. In this review, we will summarize current knowledge on the effects of estradiol, progesterone, FSH, and LH on neuronal susceptibility to pathology. We will describe ways in which the HPO axis becomes imbalanced during ovarian dysfunction, and how systemic inflammation can become an additional HPO axis effector. Finally, we will recommend solutions to the presented gaps in knowledge, and suggest avenues of future research to pursue development of therapeutics targeting both ovarian and brain health in patients.

Indexed as

AgingBrainHypothalamo-Hypophyseal SystemOvarian DiseasesOvaryAnimalsFemaleFollicle Stimulating HormoneHumansLuteinizing HormoneFollicle Stimulating HormoneLuteinizing Hormoneendocrine dysfunctiongonadotropinsneurodegenerationneuroprotectionovarian disorderssex hormones

Identifiers

PMID40884186
PMCPMC12448947

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.